Influencing factors of quality risk management of drug recall in China

doi:10.19803/j.1672-8629.20210304

Abstract

Abstract: Objective To provide suggestions for improving the quality of defective drug recalls through the extraction and importance ranking of risk factors affecting the quality of drug recalls in China. Methods Factors affecting the quality of drug recalls in China are extracted, revised, and weighted guided by risk management theory, based on literature research, using Likert scale method and analytic hierarchy process. Results and Conclusion Constructing China's drug recall quality risk index system, combining the importance of drug recall risk elements, and putting forward recommendations to control the quality risk of China's drug recalls.

Key words: drug recall, quality risk management, analytic hierarchy process, drug marketing authorization holder

CLC Number:

R954

SONG Mingyue, ZHANG Ran, WU Zhiang. Influencing factors of quality risk management of drug recall in China[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1087-1090.

References

[1] National Medical Products Administration. Measures for the administration of drug recalls (Bureau Order No. 29) [EB/OL]. (2007-12-10) [2021-03-25]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20071210000001620.html.
[2] National Medical Products Administration. Measures for the administration of drug recalls (Draft for Solicitation of Comments) [EB/OL]. (2020-10-23) [2021-03-25]. https://www.nmpa.gov.cn/xxgk/zhqyj/zhqyjyp/20201013104036103.html.
[3] JIN QY.Studies on the Project Risk Management of the R&D of New Medicines[D]. Shenyang: Shenyang Pharmaceutical University, 2006.
[4] YU YH.The Study of Biosimilars R&D Risk Management[D]. Jinan: Shandong University, 2014.
[5] SHI Y.Quality Risk Management in Pharmaceutical Cold Chain Logistics of the New GSP[D]. Jinan: Shandong University, 2014.
[6] QIAO XF.Analysis on the current situation and improvement measures of drug recall management in China[J]. Mechanical and Electrical Information(机电信息), 2018, 560(26): 12-15.
[7] National Medical Products Administration. Good manufacturing practice for drugs (Revised in2010) [EB/OL]. (2011-01-17) [2021-03-25]. https://www.nmpa.gov.cn/xxgk/fgwj/bmgzh/20110117120001434.html.
[8] BAI JF, ZHANG Z, SUN H, et al.Analysis on risk factors and preventive measures of ADR monitoring[J]. China Medicine and Pharmacy(中国医药科学), 2019, 9(18): 250-252.
[9] CAI JJ, WU QY, CHEN Q, et al.Analysis on current situation and existing problems of drug recall in China based on official website information[J]. China Pharmacy(中国药房), 2016, 27(13): 1742-1745.
[10] WENG XL, XIE RX.Practice of drug risk management in our hospital[J]. China Pharmacy(中国药房), 2015(20): 3118-3121.
[11] ZHAO JF, WANG HY, GUO Y, et al.On problems and countermeasures of the drug-recall process[J]. Chinese Pharmaceutical Affairs(中国药事), 2016, 30(1): 50-53.
[12] LI TT, WEN YL, XU J. A preliminary study on drug recall management in pharmaceutical enterprises[J]. China Market(中国市场),2015(41):108, 148.
[13] QI LB.Statistical analysis and fuzzy comprehensive evaluation of Likert scale[J]. Shandong Science(山东科学), 2006, 19(2): 18-23.
[14] XUE JZ.Research on Methods and Applications of Group Decision Making Based on Analytic Hierarchy Process[D]. Harbin: Harbin Institute of Technology, 2012.
[15] DONG XW.The Study of Municipal Solid Waste Disposal Techniques'Optimizing Based on Group Decision AHP in Chongqing city[D]. Chongqing: Chongqing University, 2016.